Uniance Gene Co., Ltd
Leap into a global company with the development based on biotechnology
Uniance Gene Co., Ltd is a
Leap into a global company with the development based on biotechnology
Global Creative Maker that realizes innovative ideas
Global leader based on human-centered philosophy that improves quality of life
2023.6
Real-time microfluid-based molecular diagnostic technology (Syndecan
gene derived from colon cancer methylation Real-time amplification POCT fluorescence diagnosis) and European CE Certification
2022.12
European CE Certification for breast cancer and overseas export
2023.6
Real-time microfluid-based molecular diagnostic technology (Syndecan
gene derived from colon cancer methylation Real-time amplification POCT fluorescence diagnosis) and European CE Certification.
2023.6
Real-time microfluidic molecular diagnosis technology (3 types of maternal-derived
birth defects) and European CE Certification.
Sogang University Convergence Research Team (Chemistry, Biology, Mechanical Engineering, Chemical Engineering, Electronic Engineering)
Korea University (Department of Molecular Biotechnology, Stem Cell & Organoid Research Team)
Yonsei University (Chemistry SynthesisTeams) - Severance Hospital.
Green Cross Gccl - Celltrion
Y-Biologics
Yonsei University, Nanoparticles, science KAIST Chemical Life
Yonsei Severance Cancer Research Center Breast cancer and Women's diseases Institution Asan Hospital Cancer Research Center
St. Mary's Hospital Breast Cancer Center
Japan Uniance Co., Ltd
USA Uniance Gene Co., Ltd (Harvard University, open schedule, 2022)
Relesed Product. No.1 UGDx COVID-19 Ag Rapid Test
Uniance Gene Co., Ltd. has developed and launched a Highly Reliable Antigen Detection Kit that helps diagnose COVID-19 infection.
COVID-19 N Antigen Rapid Test is Combining the Advantages of a Fast and Easy Lateral Flow Immunoassay with an RT-PCR diagnostic test with Accurate Sensitivity, the UGDx COVID-19 Ag Rapid Test provides Fast diagnostic speed and High Accuracy and Sensitivity.
This Test device can detect Early Stages of COVID-19 Silent Infection
2022. 12
COVID-19 Antigen Test 10 million
2022-2023
Breast cancer diagnosis 10 million, Molecular diagnosis Colon cancer 5 million Other 5 million
2023.12
List in KOSDAQ(Korea)
2026.12
List in US NASDAQ creative technology scheduled
개인정보 수집 및 이용동의 / 약관 보기
Representative Phone
82-10-8686-0257 / 82-2-6953-7741
Central R & D Center : (04107) Sogang University, Teilhard Hall, Rm 1108, 35 Baekbeom-ro, Mapo-Gu, Seoul, South Korea
Overseas business department
biojaeuniancegene@gmail.com